ALECENSA Market Summary

Key Factors Driving ALECENSA Growth

1. Major expansion into the adjuvant early-stage NSCLC setting: The most important recent growth driver is the 2024 FDA approval of ALECENSA as adjuvant therapy after tumor resection for ALK-positive NSCLC with tumors ≥4 cm or node-positive disease. The approval was based on the Phase III ALINA trial, where ALECENSA reduced the risk of disease recurrence or death by 76% (HR 0.24) versus platinum-based chemotherapy. At 2 years, 93.6% of patients receiving ALECENSA were alive and disease-free versus 63.7% with chemotherapy. This creates a substantially larger treatment opportunity beyond metastatic disease.

2. Superior first-line efficacy supports continued dominance in ALK-positive metastatic NSCLC: In the pivotal Phase III ALEX trial, ALECENSA significantly outperformed crizotinib. The 12-month PFS rate was 68.4% versus 48.7%, with a hazard ratio for progression or death of 0.47. Importantly, only 12% of patients receiving ALECENSA experienced CNS progression versus 45% with crizotinib (CNS HR 0.16). These results established alectinib as a highly effective first-line ALK inhibitor and underpin its continued use in advanced disease.

3. Strong CNS penetration is a major competitive advantage: ALK-positive NSCLC has a high propensity for brain metastases, making CNS activity particularly important. ALECENSA's strong intracranial efficacy allows it to address both systemic and CNS disease. The ALEX trial demonstrated an 84% reduction in the risk of CNS progression versus crizotinib, while the ALINA study also showed a significant CNS disease-free survival benefit in the postoperative setting (HR 0.22). This broad CNS protection strengthens its positioning across both advanced and early-stage ALK-positive NSCLC.

4. Rapid commercialization of the new adjuvant indication is expanding the addressable patient pool: Roche stated that approximately half of patients with early-stage NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy. The ALINA results therefore address a substantial unmet need by introducing targeted therapy into a setting where treatment was previously dominated by chemotherapy and observation. Roche received U.S. approval in April 2024 and European Commission approval in June 2024, with additional global submissions/approvals supporting geographic expansion.

5. Strong and growing commercial performance: Roche reported CHF 1.562 billion in ALECENSA sales in 2025, up 6% at constant exchange rates (CER) from CHF 1.548 billion in 2024. The U.S. generated CHF 565 million, growing 14%, while the International region generated CHF 531 million, up 5%. Japan contributed CHF 262 million (+7%), whereas Europe declined 6%.

The momentum has continued into 2026: H1 2026 sales reached CHF 795 million, up 6% CER, while Q1 2026 sales were CHF 401 million, up 12% CER. Roche specifically identified ALECENSA as one of the growth drivers in the International region, with the continued rollout in China contributing to growth.

ALECENSA Recent Developments

In May 2026, Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the additional indication of its anti-cancer agent/ALK inhibitor ALECENSA (generic name: alectinib) for advanced or recurrent ALK fusion gene-positive solid tumors, including pediatric patients. This is the world’s first tumor-agnostic approval for an ALK inhibitor.

“ALECENSA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ALECENSA for approved indication like Anaplastic large cell lymphoma, Non-small cell lung cancer, and Solid tumours; as well as potential indication like Brain cancer and Thyroid cancer in the 7MM. A detailed picture of ALECENSA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ALECENSA for approved and potential indications. The ALECENSA market report provides insights about ALECENSA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ALECENSA performance, future market assessments inclusive of the ALECENSA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ALECENSA sales forecasts, along with factors driving its market.

ALECENSA Drug Summary

ALECENSA is an orally administered, highly selective second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor developed by Roche/Genentech for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It inhibits ALK signaling, including ALK fusion proteins and several ALK mutations, thereby blocking pathways that promote tumor-cell proliferation and survival. ALECENSA is approved for the treatment of patients with ALK-positive metastatic NSCLC and as adjuvant therapy following tumor resection in patients with ALK-positive NSCLC at high risk of recurrence. The drug is administered as capsules, typically twice daily with food, and is notable for its ability to penetrate the central nervous system, supporting activity against brain metastases. Common adverse reactions include fatigue, constipation, muscle pain, swelling, and anemia, while clinically important risks include hepatotoxicity, interstitial lung disease/pneumonitis, bradycardia, severe muscle injury, and embryo-fetal toxicity. The report provides ALECENSA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ALECENSA Market Report

The report provides insights into:

• A comprehensive product overview including the ALECENSA MoA, description, dosage and administration, research and development activities in approved indications like Anaplastic large cell lymphoma, Non-small cell lung cancer, and Solid tumours; as well as potential indication like Brain cancer and Thyroid cancer.
• Elaborated details on ALECENSA regulatory milestones and other development activities have been provided in ALECENSA market report.
• The report also highlights ALECENSA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ALECENSA market report also covers the patents information, generic entry and impact on cost cut.
• The ALECENSA market report contains current and forecasted ALECENSA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ALECENSA market report also features the SWOT analysis with analyst views for ALECENSA in approved and potential indications.

Methodology

The ALECENSA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ALECENSA Analytical Perspective by DelveInsight

• In-depth ALECENSA Market Assessment

This ALECENSA sales market forecast report provides a detailed market assessment of ALECENSA for approved indication like Anaplastic large cell lymphoma, Non-small cell lung cancer, and Solid tumours; as well as potential indication like Brain cancer and Thyroid cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ALECENSA sales data uptil 2034.

• ALECENSA Clinical Assessment

The ALECENSA market report provides the clinical trials information of ALECENSA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ALECENSA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ALECENSA Market Potential & Revenue Forecast

• Projected market size for the ALECENSA and its key indications
• Estimated ALECENSA sales potential (ALECENSA peak sales forecasts)
• ALECENSA Pricing strategies and reimbursement landscape

ALECENSA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ALECENSA Market positioning compared to existing treatments
• ALECENSA Strengths & weaknesses relative to competitors

ALECENSA Regulatory & Commercial Milestones

• ALECENSA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ALECENSA Clinical Differentiation

• ALECENSA Efficacy & safety advantages over existing drugs
• ALECENSA Unique selling points

ALECENSA Market Report Highlights

• In the coming years, the ALECENSA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ALECENSA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ALECENSA’s dominance.
• Other emerging products for Anaplastic large cell lymphoma, Non-small cell lung cancer, and Solid tumours; as well as potential indication like Brain cancer and Thyroid cancer are expected to give tough market competition to ALECENSA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ALECENSA in approved and potential indications.
• Analyse ALECENSA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ALECENSA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ALECENSA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ALECENSA? How strong is ALECENSA’s clinical and commercial performance?
• What is ALECENSA’s clinical trial status in each individual indications such as Anaplastic large cell lymphoma, Non-small cell lung cancer, and Solid tumours; as well as potential indication like Brain cancer and Thyroid cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ALECENSA Manufacturers?
• What are the key designations that have been granted to ALECENSA for approved and potential indications? How are they going to impact ALECENSA’s penetration in various geographies?
• What is the current and forecasted ALECENSA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ALECENSA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ALECENSA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ALECENSA? What is the duration of therapy and what are the geographical variations in cost per patient?